Canada: Court Of Appeal Again Interprets Utility Requirement In Celebrex FCA

Last Updated: November 6 2014
Article by Alex Gloor


The Federal Court of Appeal has again discussed the so-called "promise doctrine" in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc., 2014 FCA 250 (Celebrex FCA). Celebrex FCA reasons that promises should be found only in circumstances where they are explicitly made. Celebrex FCA also holds that promises can only apply to those claims to which they directly relate. Celebrex FCA is especially of interest given the upcoming arguments before the Supreme Court regarding utility and the promise doctrine in Plavix.1

The Patent at Issue

Canadian Patent 2,177,576 (the '576 Patent) was at issue in Celebrex FCA. Of relevance is the fact that the '576 Patent contains claims to classes of novel compounds (claims 1-3, 7), individually claimed compounds, including the commercial compound celecoxib (claims 4-6), therapeutically-effective amounts of the claimed compounds (claim 8), and uses of the claimed compounds; in particular, the use to treat inflammation and inflammation related diseases in a subject (claims 9-15), and the use to prevent colorectal cancer (claim 16).

The claimed compounds were said to preferably be "COX-II inhibitors". A person skilled in the art knew that a selective COX-II inhibitor would potentially have lower side-effects than compounds that did not discriminate and inhibited both COX-I and COX-II. With this in mind, the patent's disclosure stated "The compounds are useful as antiinflammatory agents, such as for the treatment of arthritis, with the additional benefit of having significantly less harmful side effects" and "Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID- induced side effects."

The Decisions Below

Celebrex FCA considered two related appeals under the PM (NOC) Regulations from decisions of Justice Harrington. In the first decision, Celebrex Mylan,2 Harrington J. considered an argument that the '576 Patent promised reduced side effects, and that this promise was not in fact kept. Harrington J. rejected this argument for two reasons. First, the disclosure did not contain an explicit, unequivocal promise; only a possibility of reduced side effects was contemplated. Second, the claims themselves did not mention reduced side-effects. Given these factors, reduced side-effects was said to be a goal or advantage rather than a promise.

The second decision under appeal was Celebrex Apotex.3 Apotex argued that the use claims promised treatment of inflammation in humans (rather than "subjects", as was claimed); that reduced side-effects was a promise that pervaded all of the '576 Patent's claims; that the entire patent lacked utility because the use of claim 16, to prevent colorectal cancer, was not established; and that the '576 Patent did not meet the Patent Act's section 27(3) sufficiency requirements. Again rejecting these arguments, Harrington J. found that:

  • Use in humans to treat inflammation and a promise of reduced side-effects was not claimed;
  • While claim 16 lacked utility, section 58 of the Patent Act meant that the invalidity of this claim did not impact the validity of the other claims of the '576 Patent; and
  • The '576 Patent's true invention was a class of compounds effective as COX-II inhibitors, and thus that the '576 Patent sufficiently disclosed the invention.

The Court of Appeal's Decision

Writing for the entire panel (Trudel and Boivin JJA), Noël CJA made several interesting observations in his discussion regarding the utility of the '576 Patent. In particular, guidance was provided regarding how so-called "promises" should be appropriately construed.

The FCA stated that the general rule is that the only statutory utility requirement is found in section 2 of the Patent Act, and that section 2 only requires that a "scintilla" of utility be established. While it was found that explicit promises of specific results can represent an exception to this rule, Noël CJA cautioned courts not to be overzealous in reading in promises, stating that promises will be found "only where a clear and unambiguous promise has been made." In clarifying what constitutes a "clear and unambiguous promise", the FCA linked the Supreme Court's Consolboard4 guidance that courts, when possible, should afford protection for what was in good faith invented with Plavix FCA's dicta that promises must be "explicit". Applying this, it was stated that patents challenged on the basis of unfulfilled promises "be construed in favour of the patentee where it can be reasonably read by the skilled person as excluding this promise" and that promises will not be found if they "can only be supported on the basis of equivocal inferences and ambiguous indications."

The FCA implemented the above principles on the facts of this case to find that Harrington J. was correct in not extending the use of treating inflammation to humans, as such use was not claimed. Harrington J.'s finding that the '576 Patent made no explicit promise of reduced side effects was also upheld.

There are two other noteworthy aspects of Celebrex FCA. First, it was noted that promises do not necessarily pervade all claims of a given patent. As mentioned, the '576 Patent contained compound claims and use claims, with the use claims going to separate uses. The FCA upheld Harrington J. in finding that the lack of utility with respect to claim 16, which claimed the use of the compounds for preventing colorectal cancer, did not impact the utility of other claims, such as claim 4 (to the compound celecoxib) or claim 10 (to the use of the claimed compounds for treating inflammation in a subject). As noted in the reasons, this is entirely consistent with Gleevec5 and with the section 58 requirement in the Patent Act.6

Second, Celebrex FCA is consistent with Viagra7  and esomeprazole8 in finding that there is no need for an inventor to disclose his or her utility, including in cases of sound prediction. On this point, Noël CJA stated "the inventor need not expressly set out the utility of the invention in the is merely required that, where the inventor is called upon to prove the utility of the invention, utility can be shown to be demonstrated or soundly predicted as of the patent's filing date." This passage is consistent with the emerging recognition of the distinction between the Patent Act's section 2 utility and section 27(3) disclosure requirements.

The Celebrex FCA decision can be found here.


1 Case number 35562, on appeal from 2013 FCA 186.

2 2014 FC 38. Discussed here.

3 2014 FC 314

4 [1981] 1 SCR 504 at 521.

5 2013 FC 141

6 As recently applied in Viagra, 2012 SCC 60 at para 42.

7 At paras 38-40.

8 2014 FC 638 at paras 139-161.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.